Vitamin K2 therapy for myelodysplastic syndrome

Yasunobu Abe, Koichiro Muta, Nobuhisa Hirase, Ilseung Choi, Takamitsu Matsushima, Keiichi Hara, Fumihiro Taguchi, Eiichi Suematsu, Keisuke Shibata, Naokuni Uike, Junji Nishimura, Hajime Nawata

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Vitamin K2 is reported to induce apoptosis or differentiation of leukemic cell lines in vitro. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to 23 patients with myelodysplastic syndrome (MDS): 13 patients with RA, 2 with RARS, 6 with RAEB and 2 with RAEB-T. Good response (GR) and partial response (PR) were defined as an increase of hemoglobin concentration exceeding 2 g/dl and 1-2 g/dl without transfusion, respectively. Six of the RA patients showed improvement of anemia (GR, 3 patients; PR, 3 patients). RA patients who did not have a hypocellular bone marrow and were transfusion-independent tended to be responsive to vitamin K2 therapy in combination with vitamin D3 or anabolic steroids. No adverse effect of vitamin K2 was observed, and the time required to obtain the hematological response was short, being 3 months on average. We believe that vitamin K2 therapy has potential as a treatment for patients with MDS.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number2
Publication statusPublished - Feb 2002
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Vitamin K2 therapy for myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this